[1] Global reports on diabetes, From http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1&ua=1
2 Potterat, O. Goji (Lycium barbarum and L-chinense): Phytochemistry, Pharmacology and Safety in the Perspective of Traditional Uses and recent Popularity. Planta Medica 2010; 76:7–19.
3 Shi G J, Zheng J, Wu J, Qiao H, Chang Q, Niu Y, Sun T, Li Y, Yu J. Beneficial effects of Lycium barbarum polysaccharide on spermatogenesis by improving antioxidant activity and inhibiting apoptosis in streptozotocin-induced diabetic male mice. Food Funct 2017; 8:1215-26.
4
5 Xia H, Tang H, Wang F, Yang X, Wang Z, Liu H, Pan D, Yang C, Wang S, Sun G. An untargeted metabolomics approach reveals further insights of Lycium barbarum polysaccharides in high fat diet and streptozotocin-induced diabetic rats. Food Research International 2019; 116: 20-29.
6 Liu Q, Han Q, Lu M. Lycium barbarum polysaccharide attenuates cardiac hypertrophy, inhibits calpain-1 expression and inhibits NF-kappa B activation in streptozotocin-induced diabetic rats. Experimental and Therapeutic Medicine 2019; 18: 509-16.
7 Cai H, Liu F, Zuo P, Huang G, Song Z,Wang T, Lu H, Guo F, HanC, Sun G . Practical application of antidiabetic efficacy of lycium barbarum polysaccharide in patients with type 2 diabetes. Medicinal Chemistry 2015; 11: 383–90.
8 Wang G, Ju S, Yang B, Yan C, Cao X, Zhang X, Wang N,Lian X. Inhibitory effects and related mechanisms of lycium barbarum polysaccharides on vascular lesions in type 2 diabetes mellitus. International Journal of Clinical and Experimental Medicine 2018;11:10660-6.
9 Cai H, Yang X, Cai Q. Lycium barbarum L. Polysaccharide (LBP) Reduces Glucose Uptake via Down-Regulation of SGLT-1 in Caco2 Cell. Molecules 2017; 22: 1-12.
10 Liu M, Ouyang J, Wu K, Mao X, Li K, Guo P, YeY, Yang H, Xu Y. Effect of Astragalus polysaccharide on Ser phosphorylation of protein kinase B in skeletal muscle of KKAy mice. Medical Journal of Wuhan University 2006;27: 135-9.
11 Kumar K, Sutton G, Dong J, Roubert P, Butler A. Analysis of the therapeutic functions of novel melanocortin receptor agonists in mc3r- and mc4r-deficient c57bl/6j mice. Peptides 2009;30: 1892-900.
12 Hayase M, Ogawa Y, Katsuura G, Shintaku H, Hosoda K, Nakao K. Regulation of obese gene expression in kk mice and congenic lethal yellow obese kkay mice. American Journal of Physiology 1996; 271: 333-9.
13 Zhao R, Gao X, Zhang T, Li X. Effects of Lycium barbarum. polysaccharide on type 2 diabetes mellitus rats by regulating biological rhythms. Iranian Journal of Basic Medical Sciences 2016; 19: 1024-30.
14 Zhao R, Li Q, Xiao B. Effect of Lycium barbarum Polysaccharide on the Improvement of Insulin Resistance in NIDDM Rats. Yakugaku Zasshi 2005; 125: 981-8.
15 Rena G, Hardie D G, Pearson E R. The mechanisms of action of metformin. Diabetologia 2017; 60: 1577-85.
16 Hundal R, Krssak M, Dufour S, Laurent D, Shulman G. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-9.
17 Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: Role in Type 2 Diabetes. Clinica Chimica Acta 2012; 413: 1163-70.
18 Maedler K, Dharmadhikari G, Schumann D, Joachim S. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert opinion on biological therapy 2009; 9: 1177-88.
19 Isabelle A, Hindelang C, Benoist C, Mathis D. Cellular and molecular changes accompanying the progression from insulitis to diabetes. European journal of immunology 1999;29: 245-55.
20 Klover P, Zimmers T, Koniaris L, Mooney R. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784-9.
21 Liaqat A, Rehman K, Rasul A, Akash M. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Critical Reviews in Eukaryotic Gene Expression 2017; 27: 229-36.
22 Phosat C, Panprathip P, Chumpathat N, Prangthip P, Chantratita N, Soonthornworasiri, N. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. BMC Endocr Disord 2017; 17: 1-8.
23 Kulshrestha H, Gupta V, Mishra S, Mahdi A, Awasthi S, Chaudhry S. Interleukin-10 as a novel biomarker of metabolic risk factors. Diabetes Metab Syndr 2018; 12: 543-7.
24 Herder C, Zierer A, Koenig W, Roden M, Thorand B. Transforming growth factor- 1 and incident type 2 diabetes: results from the monica/kora case-cohort study, 1984-2002. Diabetes care 2009; 32: 1921-3.
25 Naiki Y, Michelsen K, Zhang W, Chen S, Doherty T, Arditi M . Transforming growth factor-? differentially inhibits myd88-dependent, but not tram- and trif-dependent, lipopolysaccharide-induced tlr4 signaling. Journal of Biological Chemistry 2005; 280: 5491-5.
26 Vasamsetti S, Karnewar S, Kanugula A, Thatipalli A, Kumar J, Kotamraju S. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 201; 64: 2028-41.
27 Saisho Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocr Metab Immune Disord Drug Targets 2015; 15: 1-10.
28 Cameron A, Morrison V, Levin D, Mohan M, Forteath C, Beal C. Anti-inflammatory effects of metformin irrespective of diabetes statusnovelty and significance. Circulation Research 2016; 119: 652-5.
29 Bobae H, Seulmee S, Aeri L, Sungwon, Youngcheon S, Nam-Joo H. Metformin down-regulates tnf-α secretion via suppression of scavenger receptors in macrophages. Immune Network 2013;13: 123.
30 Borowska M, Dworacka M, Wesolowska A, Winiarska H , Krzyzag?Rska E, Dworacki G. The impact of pharmacotherapy of type 2 diabetes mellitus on il-1, il-6 and il-10 secretion. Pharmacology 2016;97: 189-94.
31 Dagdeviren S, Jung D, Lee E, Friedline R, Noh H, Kim J. Altered Interleukin-10 Signaling in Skeletal Muscle Regulates Obesity-Mediated Inflammation and Insulin Resistance. Mol Cell Biol 2016; 36: 2956-66.
32 Hong E, Ko H, Cho Y, Kim H, Ma Z, Yu T. Interleukin-10 Prevents Diet-Induced Insulin Resistance by Attenuating Macrophage and Cytokine Response in Skeletal Muscle. Diabetes 2009; 58: 2525-35.
33 Moller D E. Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes. Trends Endocrinol Metab 2000;11: 212-17.
34 Akash M S H, Rehman K, Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J Cell Biochem 2018; 119: 105-10.
35 Ge JB,Lu HJ,Song XJ . Protective effects of LBP on cerebral ischemia reperfusion injury in mice and mechanism of inhibiting NF-κB, TNF-α, IL-6 and IL-1β. China Journal of Chinese Materia Medica 2017; 2:326-31.
36 Liu S Y, Chen J, Li Y F. Clinical significance of serum interleukin-8 and soluble tumor necrosis factor‐like weak inducer of apoptosis levels in patients with diabetic nephropathy. J Diabetes Investig 2018; 9: 1182-8.
37 D Zozuliñska M, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 1999; 42: 117-8.
38 Jain M, Logerfo F, Guthrie P, Pradhan L. Effect of hyperglycemia and neuropeptides on interleukin-8 expression and angiogenesis in dermal microvascular endothelial cells. J Vasc Surg 2011; 53: 1654-60.
39 Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes/metabolism Reviews 2015; 14:129-51.
40 Tabary O, Céline Muselet E, Antonicelli F, Hubert D, Dusser D. Interleukin-10 Inhibits Elevated Chemokine Interleukin-8 and Regulated on Activation Normal T Cell Expressed and Secreted Production in Cystic Fibrosis Bronchial Epithelial Cells by Targeting the I k B Kinase α/β Complex. Am J Pathol 2003; 162: 293-302.
41 Kiechl S, Wittmann J, Giaccari A. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med 2013;19:358-63.
42 Du M, Hu X, Kou L. Lycium barbarum Polysaccharide Mediated the Antidiabetic and Antinephritic Effects in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats via Regulation of NF-κB. Biomed Res Int 2016; 4: 1-9.
43 Lin J, Jing R, Pan L. Role and mechanism of mitochondrial DNA mediated Toll-like receptor 9-myeloid differentiation factor 88 signaling pathway activation in rats with ventilator-induced lung injury. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2018; 30: 13-7.
44 Han L, Li C, Sun B, Xie Y, Guan Y, Ma Z. Protective effects of celastrol on diabetic liver injury via tlr4/myd88/nf- κ b signaling pathway in type 2 diabetic rats. Journal of Diabetes Research 2016;2016:, 1-10.
45 Duan D, Zhang S, Li X , Guo H , Chen M, Zhang, Y. Activation of the TLR/MyD88/NF-κB signal pathway contributes to changes in IL-4 and IL-12 production in piglet lymphocytes infected with porcine circovirus type 2 in vitro. Plos One 2014; 9: e97653.